Abstract
Chronic, low-level lead exposure causes hypertension in both animals and humans. The pathogenesis of leadinduced hypertension is multifactorial, including such diverse mechanisms as: inactivation of endogenous nitric oxide and downregulation of soluble guanylate cyclase by reactive oxygen species (ROS), leading to a functional deficiency in nitric oxide; heightened sympathetic activity and plasma norepinephrine together with depressed vascular and elevated renal β-adrenergic receptor density; elevated plasma angiotensin-converting enzyme (ACE) activity, plasma renin activity (PRA), angiotensin II (Ang-II), and aldosterone levels; increased kininase I and kininase II activities; lead-induced inhibition of vascular smooth muscle Na+-K+ ATPase, leading to a rise in cellular Na+ and, hence, Ca2+; and a possible rise in endothelin and thromboxane generation. In this article, we present an overview of the epidemiology and proposed underlying mechanisms of lead-induced hypertension.
Similar content being viewed by others
References and Recommended Reading
Sharp DS, Osterloh J, Becker CE, et al.: Blood pressure and blood lead concentration in bus drivers. Environ Health Perspect 1988, 78:131–137.
Harlan WR: The relationship of blood lead levels to blood pressure in the U.S. population. Environ Health Perspect 1988, 78:9–13.
Khalil-Manesh F, Gonick HC, Weiler EW, et al.: Lead induced hypertension: possible role of endothelial factors. Am J Hypertens 1993, 6:723–729.
Vaziri ND, Ding Y, Ni Z, Gonick HC: Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: effect of lazaroid therapy. Kidney Int 1997, 52:1042–1046.
Gonick HC, Ding Y, Bondy SC, et al.: Lead-induced hypertension: interplay of nitric oxide and reactive oxygen species. Hypertension 1997, 30:1487–1492.
Pirkle JL, Kaufmann RB, Brody DJ, et al.: Exposure of the U.S. population to lead, 1991–1994. Environ Health Perspect 1998, 106:745–750.
Lustberg M, Silbergold E: Blood lead levels and mortality. Arch Intern Med 2002, 162:2443–2449.
Vupputuri S, Muntner P, Bazzano LA, et al.: Blood lead level is associated with elevated blood pressure in blacks. Hypertension 2003, 41:463–468.
Hond DE, Nawrot T, Staessen JA: The relationship between blood pressure and blood lead in NHANES III. J Hum Hypertens 2002, 16:563–568. Relevant broad-based evaluation of the relationship between blood lead levels and blood pressure.
Webb RC, Winquist RJ, Victery W, Vander AJ: In vivo and in vitro effects of lead on vascular reactivity in rats. Am J Physiol 1981, 241:H211-H216.
Chang HR, Chen SS, Chen TJ, et al.: Lymphocyte beta-2 adrenergic receptors and plasma catecholamine levels in lead-exposed workers. Toxicol Appl Pharmacol 1996, 139:1–5.
Castellino N, Castellino P, Sannolo N: Inorganic Lead Exposure: Metabolism and Intoxication. Boca Raton: Lewis Publisher, 1995.
Sokas RK, Simmens S, Sophar K, et al.: Lead levels in Maryland construction workers. Am J Ind Med 1997, 31:188–194.
Menditto A, Morisi G, Spagnolo A, Mencotti A: Association of blood lead to blood pressure in men aged 55 to 75 years: effects of selected social and biochemical cofounders. Environ Health Perspect 1994, 102:107–111.
Hu H, Aro A, Payton M, et al.: The relationship of bone and blood lead to hypertension: the normative aging study. JAMA 1996, 275:1171–1176.
Shen X, Rosen JF, Guo D, Wu S: Childhood lead poisoning in China. Sci Total Environ 1996, 181:101–109.
Postoli P, Maranelli G, Micciolo R: Is hypertension a confounding factor in the assessment of blood lead reference values? Sci Total Environ 1992, 120:127–134.
Moller L, Kristensen TS: Blood lead as a cardiovascular risk factor. Am J Epidemiol 1992, 136:1091–1100.
Pirkle JL, Schwartz J, Landis JR, Harlan WR: The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. Am J Epidemiol 1985, 121:246–258.
Rothenberg SJ, Kondrashov V, Manalo M, et al.: Increases in hypertension and blood pressure during pregnancy with increased bone lead levels. Am J Epidemiol 2002, 156:1079–1087.
Glenn BS, Stewart WF, Links JM, et al.: The longitudinal association of lead with blood pressure. Epidemiology 2003, 14:30–36.
Nash D, Magder L, Lustberg L, et al.: Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. J Am Med Assoc 2003, 289:1523–1532. Careful delineation of blood lead and blood pressure associations in relation to menopausal status.
Staessen JA, Roels H, Lauwerys RR, Amery A: Low-level lead exposure and blood pressure. J Hum Hypertens 1995, 9:303–328.
Hu H: Poorly controlled hypertension in a painter with chronic lead toxicity. Environ Health Perspect 2001, 109:95–99.
Nilsson U, Attewell R, Christoffersson JO, et al.: Kinetics of lead in the bone and blood after the end of occupational exposure. Pharmacol Toxicol 1991, 68:477–484.
Rothenberg SJ, Kondrashov V, Manalo M, et al.: Increases in hypertension and blood pressure during pregnancy with increased bone lead levels. Am J Epidemiol 2002, 156:1079–1087.
Webber CE, Chettle DR, Bowins RJ, et al.: Hormone replacement therapy may reduce the return of endogenous lead from bone to the circulation. Environ Health Perspect 1995, 103:1150–1153.
Garrido Latorre F, Hernandez-Avila M, Tamayo Orozco J, et al.: Relationship of blood and bone lead to menopause and bone mineral density among middle-age women in Mexico City. Environ Health Perspect 2003, 111:631–636.
Fleet JC: Bone lead as a risk factor for hypertension in men. Nutr Rev 1996, 54:180–182.
Batuman V: Lead nephropathy, gout and hypertension. Am J Med Sci 1993, 305:241–247.
Houston DK, Johnson MA: Lead as a risk factor for hypertension in women. Nutr Rev 1999, 57:227–279.
Cheng Y, Schwartz J, Sparrow D, et al.: Bone lead and blood lead levels in relation to baseline blood pressure and the prospective development of hypertension: the normotensive aging study. Am J Epidemiol 2001, 153:164–171.
Muntner P, He J, Vupputuri S, et al.: Blood lead and chronic kidney disease in the general United States population: results from NHANES III. Kidney Int 2003, 63:1044–1050.
Vaziri ND, Ding Y, Ni Z: Nitric oxide synthase expression in the course of lead-induced hypertension. Hypertension 1999, 34:558–562.
Vaziri ND, Liang K, Ding Y: Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int 1999, 56:1492–1498.
Dijkhorst-Oei LT, Koomans HA: Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. Nephrol Dial Transplant 1998, 13:587–593.
Harada S, Tokunaga S, Momohara M, et al.: Inhibition of nitric oxide formation in the nucleus tractus solitarius increases renal sympathetic nerve activity in rabbits. Circ Res 1993, 72:511–516.
Qiu C, Muchant D, Beierwaltes WH, et al.: Evolution of chronic nitric oxide inhibition hypertension: relationship to renal function. Hypertension 1998, 31:21–26.
Halliwell B: What nitrates tyrosine?: Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett 1997, 411:157–160.
Ding Y, Gonick HC, Vaziri ND, et al.: Lead-induced hypertension: Increased hydroxyl radical production. Am J Hypertens 2001, 14:169–173.
Vaziri ND, Oveisi F, Ding Y: Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int 1998, 53:1748–1754.
Vaziri ND, Ni Z, Oveisi F, et al.: Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2001, 39:135–141.
Schnackenberg CG, Welch WJ, Wilcox CS: Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 1998, 32:59–64.
Schnackenberg CG, Wilcox CS: Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha. Hypertension 1999, 33:424–428.
Vaziri ND, Ni Z, Oveisi F, Tarnavsky-Hobbs DL: Effect of antioxidant therapy on blood pressure and nitric oxide synthase expression in hypertensive rats. Hypertension 2000, 36:975–964.
Lopez-Ongil S, Hernandez-Perera O, Navarro-Antolin J, et al.: Role of reactive oxygen species in the signaling cascade of cyclosporine A-mediated up-regulation of eNOS in vascular endothelial cells. Br J Pharmacol 1998, 124:447–454.
Roberts CK, Vaziri ND, Wang XQ, Barnard RJ: Enhanced NO inactivation and hypertension induced by a high-fat, refined carbohydrate diet. Hypertension 2000, 36:423–429.
Roberts CK, Vaziri ND, Liang K, Barnard RJ: Reversibility of chronic experimental syndrome X by diet modification. Hypertension 2000, 37:1323–1328.
Barton CH, Ni Z, Vaziri ND: Effect of server aortic banding above the renal arteries on nitric oxide synthase isotype expression. Kidney Int 2001, 59:654–661.
Barton CH, Ni Z, Vaziri ND: Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension. Kidney Int 2001, 60:1083–1087.
Swei A, Lacy F, DeLano FA, Schmid-Schonbein GW: Oxidative stress in the Dahl hypertensive rat. Hypertension 1997, 30:1628–1633.
Roggensack AM, Zhang Y, Davidge ST: Evidence for peroxynitrite formation in the vasculature of women with preeclampsia. Hypertension 1999, 33:83–89.
Vaziri ND, Ding Y, Ni Z: Compensatory upregulation of NO synthase isoforms in lead-induced hypertension: reversal by an SOD-mimetic drug. J Pharmacol Exp Therap 2001, 298:679–685.
Vaziri ND, Wang XQ, Oveisi F, Rad B: Induction of oxidative stress by glutathione depletion causes hypertension in normal rats. Hypertension 2000, 36:142–146.
Vaziri ND, Wang XQ: cGMP-mediated negative feedback regulation of endothelial nitric oxide synthase expression by nitric oxide. Hypertension 1999, 34:1237–1241.
Ding Y, Gonick HC, Vaziri ND: Lead promotes hydroxyl radical generation and lipid peroxidation in cultured aortic endothelial cells. Am J Hypertens 2000, 13:552–555.
Ding Y, Vaziri ND, Gonick HC: Lead-induced hypertension. II. Response to sequential infusions of L-arginine, superoxide dismutase, and nitroprusside. Environ Res 1998, 76:107–113.
Vaziri ND, Ding Y: Effect of lead on NO synthase expression in coronary endothelial cells: Role of superoxide. Hypertension 2001, 37:223–226.
Hsu PC, Guo YL: Antioxidant nutrients and lead toxicity. Toxicology 2002, 180:33–44. Comprehensive discussion of the role of antioxidants in modifying the effects of lead toxicity.
Vaziri ND, Lin CY, Farmand F, Sindhu R: Superoxide dismutase, catalase, glutathione peroxidase and NADPH oxidase in lead-induced hypertension. Kidney Int 2003, 63:186–194.
Marques M, Millas I, Jimenez A, et al.: Alteration of the soluble guanylate cyclase system in the vascular wall of lead-induced hypertension in rats. J Am Soc Nephrol 2001, 12:2594–2600.
Courtois E, Marques M, Barrientos A, et al.: Lead-induced downregulation of soluble guanylate cyclase in isolated rat aortic segments mediated by reactive oxygen species and cycloxygenase-2. J Am Soc Nephrol 2003, 14:1464–1470. Description of the effect of lead-induced change in reactive oxygen species on soluble guanylate cyclase.
Chang HR, Chen SS, Tsao DA, et al.: Reduced vascular betaadrenergic receptors and catecholamine response in rats with lead-induced hypertension. Arch Toxicol 1977, 71:778–781.
Carmignani M, Volpe AR, Boscolo P, et al.: Catecholamine and nitric oxide systems as targets of chronic lead exposure in inducing selective functional impairment. Life Sci 2000, 68:401–415.
Tsao DA, Yu HS, Cheng JT, et al.: The change of beta-adrenergic system in lead-induced hypertension. Toxicol Appl Pharmacol 2000, 164:124–133.
Bertel O, Buhler FR, Ott J: Lead-induced hypertension: Blunted beta-adrenoceptor-mediated functions. Br Med J 1978, 1:551.
Keeton TK, Campbell WB: The pharmacologic alteration of renin release. Pharmacol Rev 1980, 32:81–227.
McAllister RG, Michelakis AM, Sandstead HH: Plasma renin activity in chronic plumbism. Arch Intern Med 1971, 127:919–923.
Boscolo P, Carmignani M: Neurohumoral blood pressure regulation in lead exposure. Environ Health Perspect 1988, 78:101–106.
Fleischer N, Mouw DR, Vander AJ: Chronic effects of lead on renin and renal sodium excretion. J Lab Clin Med 1980, 95:759–770.
Wilke L: Early and Late Effects of Neonatal Lead Exposure or In Vitro Renin Release [bstract]. Thorofare, NJ: American Society of Nephrology; 1987.
Nowack R, Wiecek A, Ritz E: Lead and hypertension. Contrib Neprhol 1992, 100:25–34.
Carmignani M, Boscolo P, Brandi G: Plasma renin activity to occupational lead exposure. Acta Med Rom 1988, 26:277–289.
Camignani M, Boscolo P, Poma A, Volpe AR: Kininergic system and arterial hypertension following chronic exposure to inorganic lead. Immunopharmacol 1999, 44:105–110.
Terada Y, Tomita K, Nonoguchi H, et al.: Expression of endothelin-3 RNA along rat nephron segments using polymerase chain reaction. Kidney Int 1993, 44:1273–1280.
Cardenas A, Roels H, Bernard AM, et al.: Markers of early renal changes induced by industrial pollutants. II. Application to workers exposed to lead. Br J Ind Med 1993, 50:28–36.
Hotter G, Fels LM, Closa D, et al.: Altered levels of urinary prostanoids in lead-exposed worker. Toxicol Lett 1995, 77:309–312.
Gonick HC, Ding Y, Vaziri ND: Effect of low lead exposure on eicosanoid excretion in rats. Prost Lipid Med 1998, 55:77–82.
Piccinini F, Favalli L, Chiari MC: Experimental investigations on the contraction induced by lead in arterial smooth muscle. Toxicology 1977, 8:43–51.
Kramer HJ, Gonick HC, Lu E: In vitro inhibition of Na-KATPase by trace metals: relation to renal and cardiovascular damage. Nephron 1986, 44:329–366.
Snowdon CT, Sanderson BA: Lead pica produced in rats. Science 1974, 193:92–94.
Mahaffey KR, Goyer R: Dose-response to lead ingestion in rats fed low dietary calcium. J Lab Clin Med 1973, 82:92–100.
Aungst BJ, Fung HL: The effects of dietary calcium on lead absorption, distribution and elimination kinetics in rats. J Toxicol Environ Health 1985, 16:147–159.
Hwang KY, Schwartz BS, Lee BK, et al.: Associations of lead exposure and dose measures with erythrocyte protein kinase C activity in 212 current Korean lead workers. Toxicol Sci 2001, 62:280–288.
Watts SW, Chai S, Webb RC: Lead acetate-induced contraction in rabbit mesenteric artery: interaction with calcium and protein kinase C. Toxicology 1995, 99:55–65.
Chai SS, Webb RC: Effects of lead on vascular reactivity. Environ Health Perspect 1988, 78:85–89.
Shelkovnikov SA, Gonick HC: Influence of lead on rat thoracic aorta contraction and relaxation. Am J Hypertension 2001, 14:873–878.
Griffith LE, Guyatt GH, Cook RJ, et al.: The influence of dietary and non-dietary calcium supplementation on blood pressure: an updated meta-analysis of randomised controlled trials. Am J Hypertens 1999, 12:84–92.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vaziri, N.D., Sica, D.A. Lead-induced hypertension: Role of oxidative stress. Current Science Inc 6, 314–320 (2004). https://doi.org/10.1007/s11906-004-0027-3
Issue Date:
DOI: https://doi.org/10.1007/s11906-004-0027-3